RxDoctor Payments Data

Andrew Solkovits, DO

Family Medicine · Redding, CANPI 1487643250

Payments from drug & device makers

$15,549in general payments, 2019–2025

Across 821 payments — averaging $18.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Senseonics, Incorporated$1K
  • AstraZeneca$1K
  • Pfizer$1K
  • Boehringer Ingelheim$885
  • Novo Nordisk$860
  • plus $7K from 54 others

What the payments were for

  • Speaking & faculty fees$1,2008%
  • Food & beverage$14,01390%
  • Education$3222%
  • Gifts$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)200$3,716
Senseonics, Incorporated1$1,200
AstraZeneca34$1,170
Pfizer78$1,107
Boehringer Ingelheim44$885
Novo Nordisk60$860
Amgen38$775
Lilly USA, LLC42$746
Takeda Pharmaceuticals U.S.A., Inc.25$381
GSK21$334
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC23$332
Biohaven Pharmaceutical Holding Company Ltd.42$329
Merck17$272
Biohaven Pharmaceuticals, Inc.38$264
Daiichi Sankyo Inc.15$259
Mylan Specialty L.p.11$228
Madrigal Pharmaceuticals3$178
Si-bone, Inc.2$157
Otsuka America Pharmaceutical, Inc.7$157
Bayer8$129
Exact Sciences8$128
Axsome Therapeutics, Inc.6$125
Nestle Healthcare Nutrition Inc.5$124
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)7$123
Idorsia Pharmaceuticals US Inc8$117
Sanofi Pasteur Inc.8$114
Johnson & Johnson6$111
Corcept Therapeutics5$105
Astellas Pharma US Inc4$81
Abbott4$81
Medtronic1$74
Ascensia Diabetes Care US Inc.3$60
Xeris Pharmaceuticals, Inc.3$53
QOL Medical, LLC4$49
Vanda Pharmaceuticals Inc.2$40
Phathom Pharmaceuticals, Inc.2$39
Lundbeck LLC2$38
Vertex2$38
Esperion Therapeutics, Inc.2$38
Therapeuticsmd, Inc.2$38
Kowa Pharmaceuticals America, Inc.2$35
Irhythm Technologies, Inc.2$33
GE HealthCare2$32
Aimmune Therapeutics, Inc.2$31
Sanofi1$26
C2n Diagnostics, LLC1$24
Edwards Lifesciences1$24
IBSA Pharma Inc.1$23
Tandem Diabetes Care, Inc.1$22
Impel Pharmaceuticals Inc.1$21
Amarin Pharma, Inc.1$20
Viatris Specialty LLC1$20
Almatica Pharma LLC1$19
Collegium Pharmaceutical, Inc.1$18
Upsher-smith Laboratories LLC1$18
Biomarin Pharmaceutical Inc.1$17
Gilead1$16
Verity Pharmaceuticals Inc.1$15
AMAG Pharmaceuticals, Inc.1$15
Biodelivery Sciences International, Inc.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,549 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$1,398,976
Medicare patients
1,584
Services billed
12,126

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide88$124,909
EliquisApixaban89$101,431
Trelegy ElliptaFluticasone/Umeclidin/Vilanter57$68,426
JardianceEmpagliflozin37$53,286
FarxigaDapagliflozin Propanediol49$43,467
TrulicityDulaglutide32$36,408
MounjaroTirzepatide21$23,624
RexultiBrexpiprazole15$21,226
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog16$17,089
Synjardy XrEmpagliflozin/Metformin Hcl21$12,531
TradjentaLinagliptin17$11,578
XareltoRivaroxaban14$11,355
Dexlansoprazole DrDexlansoprazole13$7,551
FingolimodFingolimod Hcl12$6,868
SynthroidLevothyroxine Sodium101$6,725

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$860$124,90988 claims
PfizerEliquis$1,107$101,43189 claims
Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta$885$77,39475 claims
GSKTrelegy Ellipta$334$68,42657 claims
Lilly USA, LLCTrulicity, Mounjaro$746$60,03353 claims
AstraZenecaFarxiga$1,170$43,46749 claims
Otsuka America Pharmaceutical, Inc.Rexulti$157$21,22615 claims
Johnson & JohnsonXarelto$111$11,35514 claims
AbbVieSynthroid$3,716$6,725101 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.

Other family medicine in Redding

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →